Etrasimod for ulcerative colitis in older adults

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This single-center interventional study will give etrasimod to elderly patients with active ulcerative colitis identified during routine clinical practice and prospectively collect clinical course, adverse events, endoscopic findings, and biopsy histopathology. Eligible patients provide written informed consent and are followed with standard clinical assessments and endoscopy as part of care. Patients with significant comorbidities such as renal failure, chronic heart disease, pulmonary infection, liver cirrhosis, colorectal cancer, autoimmune disease, or active infections are excluded. The open-label design aims to generate real-world safety and effectiveness data specific to an older patient population.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients with active ulcerative colitis

Exclusion Criteria:

* the presence of acute or chronic renal failure, chronic heart disease, pulmonary infection, liver cirrhosis, colorectal cancer, autoimmune disease, and infectious disease

Where it's running

• Showa Inan General Hospital
  Komagane, Nagano, Japan Recruiting

Study contacts

• Study coordinator: Norio Saegusa
• Email: ikyoku.tosho@sihp.jp
• Phone: 81265822121

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Mediterranean Diet and Time-Restricted Feeding in Ulcerative Colitis in Remission

  This study tests whether a Mediterranean diet, with or without an 8-hour eating window, helps gut health and quality of life in adults with ulcerative colitis in remission.

  Recruiting Pontificia Universidad Catolica de Chile · Santiago, Santiago Metropolitan · NCT07752446

• Guselkumab in Moderate-to-Severe Ulcerative Colitis: Real-World Experience

  This real-world study tests whether guselkumab helps adults with moderate-to-severe ulcerative colitis and how safe it is for them.

  Recruiting Second Affiliated Hospital of Wenzhou Medical University · Wenzhou, Zhejiang · NCT07726888

• BDHK-2009 safety test in healthy adults

  This early-stage test checks if BDHK-2009 tablets are safe and tolerable in healthy adults aged 18–55 compared with placebo.

  Recruiting Phase 1 Benethera (Shaoxing) Biotechnology Co., Ltd. · Hangzhou, Zhejiang · NCT07632573

• ButyMixx for Ulcerative Colitis in Remission

  This study tests ButyMixx, a supplement with sodium butyrate and a beneficial yeast, to see if it helps people with ulcerative colitis in remission feel better and keep inflammation low.

  Recruiting University of Padova · Padova · NCT07591012

• Partial enteral nutrition to help IBD patients at nutritional risk maintain weight

  We’re testing whether adding an oral nutritional supplement (LH VIOLA) to standard counseling helps adults with IBD who are at risk of malnutrition keep or gain weight over 16 weeks.

  Recruiting at 4 sites Lionhealth Srl Società Benefit · Rozzano, Milano and 3 other locations · NCT07433946

• Pomegranate juice for mild-to-moderate ulcerative colitis

  The goal is to see if drinking 237 ml of pomegranate juice every day for 8 weeks lowers inflammation and changes gut microbes in adults with mild-to-moderate ulcerative colitis.

  Recruiting University of California, Los Angeles · Los Angeles, California and 1 other locations · NCT07115862

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.